Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01999842
Other study ID # 201072
Secondary ID
Status Completed
Phase Phase 1
First received November 21, 2013
Last updated May 26, 2017
Start date November 25, 2013
Est. completion date January 19, 2015

Study information

Verified date May 2017
Source GlaxoSmithKline
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and immunogenicity of different formulations of GSK Biologicals' H7N9 influenza vaccine in subjects 18 to 64 years of age.


Recruitment information / eligibility

Status Completed
Enrollment 424
Est. completion date January 19, 2015
Est. primary completion date February 1, 2014
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 64 Years
Eligibility Inclusion Criteria:

- Male or female adults who are 18 to 64 years of age (inclusive) at the time of first study vaccination.

- Written informed consent obtained from subject.

- Subjects who the investigator believes can and will comply with the requirements of the protocol .

- Healthy subjects as established by medical history and physical examination.

- Access to a consistent means of telephone contact.

- For subjects who undergo a screening visit: results of all safety laboratory tests obtained at the screening visit must be within reference ranges. Results of any repeat testing cannot be used to qualify a subject for enrolment.

- Female subjects of non-childbearing potential may be enrolled in the study. Non-childbearing potential is defined as current tubal ligation, hysterectomy, ovariectomy or post-menopause.

- Female subjects of childbearing potential may be enrolled in the study, if they

- have practiced adequate contraception for 30 days prior to vaccination, and

- have a negative pregnancy test on the day of vaccination, and

- agree to continue to practice adequate contraception until 2 months after the last dose administered.

Exclusion Criteria:

- Presence or evidence of neurological or psychiatric diagnoses which, although stable, are deemed by the investigator to render the potential subject unable/unlikely to provide accurate safety reports.

- Presence or evidence of substance abuse.

- Diagnosed with cancer, or treatment for cancer within three years.

- Diagnosed with excessive daytime sleepiness, or narcolepsy; or history of narcolepsy in a subject's parent, sibling or child.

- Presence of a temperature = 38.0ºC (=100.4ºF), or acute symptoms greater than "mild" severity on the scheduled date of first vaccination.

- Any confirmed or suspected immunosuppressive or immunodeficient condition including history of human immunodeficiency virus (HIV) infection.

- Receipt of systemic glucocorticoids within 30 days prior to the first dose of study vaccine/placebo, or any other cytotoxic, immunosuppressive or immune-modifying drugs within 6 months of first study vaccine/ placebo dose.

- Any significant disorder of coagulation or treatment with warfarin derivatives or heparin.

- An acute evolving neurological disorder or Guillain Barré Syndrome within 42 days of receipt of prior seasonal or pandemic influenza vaccine.

- Administration of an inactive vaccine within 14 days or of a live attenuated vaccine within 30 days before the first dose of study vaccine/placebo.

- Planned administration of any vaccine other than the study vaccine/placebo before blood sampling at the Day 42 visit.

- Previous administration of any H7 vaccine or physician-confirmed H7 disease.

- Use of any investigational or non-registered product other than the study vaccine within 30 days preceding the first dose of study vaccine/placebo, or planned use during the study period.

- Receipt of any immunoglobulins and/or any blood products within 90 days before the first dose of study vaccine/placebo, or planned administration of any of these products during the study period.

- Any known or suspected allergy to any constituent of influenza vaccines or component used in the manufacturing process of the study vaccine including a history of anaphylactic-type reaction to consumption of eggs; or a history of severe adverse reaction to a previous influenza vaccine.

- Known pregnancy or a positive urine beta-human chorionic gonadotropin (ß-hCG) test result before the first dose of study vaccine/placebo.

- Lactating or nursing women.

- Any condition which, in the opinion of the investigator, prevents the subject from participating in the study.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Investigational H7N9 vaccine GSK3206641A
One dose of GSK3206641A H7N9 vaccine administered intramuscularly (IM) in the deltoid region of arm at Day 0 and the second dose of GSK3206641A H7N9 vaccine administered IM in the deltoid region of arm at Day 21
Investigational H7N9 vaccine GSK3206640A
One dose of GSK3206640A H7N9 vaccine administered IM at the deltoid region of arm at Day 0 and the second dose of GSK3206640A H7N9 vaccine administered IM at the deltoid region of arm at Day 21
Placebo
One dose of placebo administered IM at the deltoid region of arm at Day 0 and the second dose of placebo administered IM at the deltoid region of arm at Day 21

Locations

Country Name City State
Canada GSK Investigational Site Sherbrooke Quebec
Canada GSK Investigational Site Truro Nova Scotia
Canada GSK Investigational Site Woodstock Ontario
United States GSK Investigational Site Boise Idaho
United States GSK Investigational Site Erie Pennsylvania
United States GSK Investigational Site Jacksonville Florida
United States GSK Investigational Site Seattle Washington
United States GSK Investigational Site Stockbridge Georgia

Sponsors (1)

Lead Sponsor Collaborator
GlaxoSmithKline

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Humoral immune response in terms of vaccine-homologous hemagglutination inhibition (HI) antibody titers The following aggregate variables will be calculated for each adjuvanted H7N9 vaccine group: • Seroconversion rates (SCR); • Seroprotection rates (SPR); • Mean Geometric Increase (MGI) At Day 42
Primary Occurrence of each solicited local symptom During a 7-day follow-up period (i.e., day of vaccination and 6 subsequent days) after each vaccination
Primary Occurrence of each solicited general symptom During a 7-day follow-up period (i.e., day of vaccination and 6 subsequent days) after each vaccination
Primary Occurrence of clinical safety laboratory abnormalities reported for samples At Day 0 visit
Primary Occurrence of clinical safety laboratory abnormalities reported for samples At Day 7 visit
Primary Occurrence of clinical safety laboratory abnormalities reported for samples At Day 21 visit
Primary Occurrence of clinical safety laboratory abnormalities reported for samples At Day 28 visit
Primary Occurrence of clinical safety laboratory abnormalities reported for samples At Day 42 visit
Primary Occurrence of unsolicited adverse events 21 days after each dose
Primary Occurrence of Medically Attended Adverse Events (MAEs), potential Immune Mediated Diseases (pIMDs) and Serious Adverse Events (SAEs) From Day 0 until the Day 42
Secondary Humoral immune response in terms of vaccine-homologous hemagglutination inhibition (HI) antibody titers The following aggregate variables will be calculated for each adjuvanted (GSK3206641A) vaccine group which successfully meets CBER and CHMP criteria, and for the unadjuvanted (GSK3206640A) plain antigen vaccine group: • Geometric mean reciprocal serum HI antibody titers (GMTs); • SCR At Day 42
Secondary Humoral immune response in terms of vaccine-homologous hemagglutination inhibition (HI) antibody titers The following aggregate variables will be calculated for the unadjuvanted plain antigen vaccine group: • SCR; • SPR; • MGI At Day 42
Secondary Humoral immune response in terms of vaccine-homologous (H7N9) HI antibody titers The following aggregate variables will be calculated for each study group: • GMTs; • Seropositivity rates; • SCR; • SPR; • MGI GMTs and Seropositivity rates at Days 0, 21, 42 and Months 6 and 12; SCR and MGI at Day 21, 42 (Placebo group only) and Months 6 and 12; SPR at Days 0, 21, 42 (Placebo group only) and Months 6 and 12
Secondary Humoral immune response in terms of vaccine-homologous (H7N9) HI antibody titers by age stratum The following aggregate variables will be calculated for each study group by age stratum (18-40 years; 41-64 years): • GMTs; • Seropositivity rates; • SCR; • SPR; • MGI GMTs, Seropositivity rates and SPR at Days 0, 21, 42 and Months 6 and 12; SCR and MGI at Day 21, 42 and Months 6 and 12
Secondary Humoral immune response in terms of vaccine homologous (H7N9) neutralizing (MN) antibody titers The following parameters will be calculated for a subset of subjects in each study group: • GMTs; • Seropositivity rates; • Vaccine response rate (VRR) GMTs and Seropositivity rates at Days 0, 21, 42 and Month 6; VRR at Days 21, 42 and Month 6
Secondary Occurrence of MAEs, pIMDs and SAEs Until the Month 12 visit
See also
  Status Clinical Trial Phase
Completed NCT05523089 - The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults Phase 2
Completed NCT05009251 - Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake N/A
Completed NCT03282240 - Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US Phase 3
Completed NCT00968526 - Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults Phase 3
Completed NCT00968539 - Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults Phase 3
Completed NCT00971425 - Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1) Phase 3
Completed NCT05525494 - Patient Portal Flu Vaccine Reminders (5) N/A
Completed NCT04074928 - Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects Phase 3
Completed NCT04695717 - This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam Phase 3
Completed NCT05012163 - Lottery Incentive Nudges to Increase Influenza Vaccinations N/A
Completed NCT03888989 - Response to Influenza Vaccine During Pregnancy Phase 1
Completed NCT04109222 - Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively Phase 4
Completed NCT02587221 - Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age Phase 3
Completed NCT03453801 - The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection Phase 1
Completed NCT01440387 - A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older Phase 3
Terminated NCT01195779 - Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children Phase 2
Completed NCT03321968 - Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults Phase 3
Completed NCT00972517 - Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children Phase 3
Completed NCT04570904 - Broadening Our Understanding of Early Versus Late Influenza Vaccine Effectiveness
Recruiting NCT03331991 - Prevention of Influenza and Other Wintertime Respiratory Viruses Among Healthcare Professionals in Israel N/A